PerkinElmer Inc. expanded the company’s presence in cell biology with the $260 million acquisition of Massachusetts-based Nexcelom Bioscience.

With Lyme disease season emerging and the Covid-19 pandemic still with us, an important webinar designed to help physicians differentiate between the two (as well as the flu) so as to provide timely diagnosis and treatment for their patients will be held on Wednesday, May 5. The webinar is the latest in an ongoing series sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions.

AstraZeneca and Sanofi announced that their MELODY Phase III trial of nirsevimab hit the primary endpoint in medically attended lower respiratory tract infections (LRTI) caused by respiratory syncytial virus (RSV) in healthy late preterm and term infants. RSV infections cause about 80,000 hospitalizations in children and 500 deaths each year. 

Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).

None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.

The U.S. Food and Drug Administration approved Melinta Therapeutics’ Kimyrsa (oritavancin) for the treatment of adults with acute bacterial skin and skin structure infections caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus.

A majority of Covid-19 patients that were admitted to U.S. hospitals during the first few months of the pandemic were prescribed antibiotics even before a bacterial infection had been confirmed, a study showed on March 10.

Researchers at Northwestern University identified a compound that appears to reverse the ongoing degeneration of upper motor neurons associated with amyotrophic lateral sclerosis (ALS).

The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.

Paris-based Ipsen secured Fast Track designation from the U.S. Food and Drug Administration for Onivyde (irinotecan liposome injection) for study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen.